4-methoxy-N-{2-[1-(piperidin-1-yl)propan-2-yl]phenyl}benzamide

• ChemBase ID: 1097
• Molecular Formular: C22H28N2O2
• Molecular Mass: 352.46992
• Monoisotopic Mass: 352.21507815
• SMILES: O=C(Nc1c(C(CN2CCCCC2)C)cccc1)c1ccc(OC)cc1
• Canonical SMILES: COc1ccc(cc1)C(=O)Nc1ccccc1C(CN1CCCCC1)C
• InChI: InChI=1S/C22H28N2O2/c1-17(16-24-14-6-3-7-15-24)20-8-4-5-9-21(20)23-22(25)18-10-12-19(26-2)13-11-18/h4-5,8-13,17H,3,6-7,14-16H2,1-2H3,(H,23,25)
• InChIKey: VOVAEUFPROBLAL-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 4-methoxy-N-{2-[1-(piperidin-1-yl)propan-2-yl]phenyl}benzamide
• IUPAC Traditional name: (+)-isomer encainide
• Brand Name: Enkaid
• Synonyms: Encainida [Spanish]; Encainide [French]; Encainidum [Latin]; Encainide

Database IDs

• CAS Number: 66778-36-7
• PubChem SID: 160964560
• PubChem CID: 48033

CALCULATED PROPERTIES

JChem

• Acid pKa: 12.276945
• H Acceptors: 3
• H Donor: 1
• LogD (pH = 5.5): 1.0392171
• LogD (pH = 7.4): 2.4888701
• Log P: 4.352856
• Molar Refractivity: 107.966 cm^3
• Polarizability: 40.920128 Å^3
• Polar Surface Area: 41.57 Å^2
• Rotatable Bonds: 6
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 4.63
• LOG S: -4.87
• Solubility (Water): 4.77e-03 g/l

PROPERTIES

Physical Property

• Hydrophobicity(logP): 4

DETAILS

DrugBank - DB01228

• Drug Groups: approved; withdrawn
• Description: All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
• Indication: Encainide is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.
• Pharmacology: Used to treat irregular heartbeats, encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje system. Encainide decreases the rate of rise of the action potential without markedly affecting its duration.
• Affected Organisms: Humans and other mammals
• Half Life: 1-2 hours
• Elimination: A radiolabeled dose of encainide is excreted in approximately equal amounts in the urine and feces.
• External Links: Wikipedia